Zinzino Preliminary Sales Report October 2025: Revenue increased a total of 65 %, as compared with the previous year.
The revenue in October for Zinzino‘s sales markets increased by 70 % and amounted to SEK 324.8 (191.6) million. Faun Pharma’s external sales decreased and amounted to SEK 2.7 (7.3) million.
Overall, the Group increased revenues by 65 % to SEK 327.5 (198.9) million compared with the previous year.
Accumulated revenue for January – October 2025 increased by 55 % to SEK 2,629.7 (1,693.2) million.
Revenues were distributed as follows:
Regions, MSEK
25-Oct
24-Oct
Change
YTD 2025
YTD 2024
Change
The Nordics
36.3
29.3
24%
270.3
243.3
11%
Central Europe
101.3
53.9
88%
758.9
448.3
69%
East Europe
34.4
34.5
0%
310.3
314.4
-1%
South & West Europe
57.8
37.0
56%
455.8
301.5
51%
The Baltics
13.0
10.1
29%
98.2
79.5
24%
North America
51.6
19.3
167%
433.6
153.3
183%
Asia-Pacific
28.1
5.8
384%
241.3
53.3
353%
Africa
2.3
1.7
35%
18.3
12.6
45%
Zinzino
324.8
191.6
70%
2586.7
1606.2
61%
Faun Pharma
2.7
7.3
-63%
43.0
87.0
-51%
Zinzino Group
327.5
198.9
65%
2629.7
1693.2
55%
Countries in regions:
– The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
– Central Europe: Austria, Germany, Switzerland
– East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
– South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
– The Baltics: Estonia, Latvia, Lithuania
– North America: Canada, USA, Mexico
– Asia-Pacific: Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines
– Africa: South Africa
SOURCE: Zinzino
About Zinzino
Zinzino AB (publ) (ZZ-B.ST) is a global direct-sales company from Scandinavia specializing in test-based, personalized nutrition and scientific skincare. It is a public limited company with its shares listed on